Cargando…

A Novel Aurora-A Inhibitor, BPR1K0609S1, Sensitizes Colorectal Tumor cells to 5-Fluorofracil (5-FU) Treatment

Mostrar otras versiones (1)

Small synthetic compounds have been implicated in treatment of human cancers. We have synthesized a small compound, BPR1K0609S1 (hereafter, BP), which inhibits Aurora-A kinase. In the present study, we studied the mechanism of BP suppression of tumorigenesis induced by Aurora-A. Given our previous r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shionome, Yoshimi, Lin, Wen-Hsing, Shiao, Hui-Yi, Hsieh, Hsing-Pang, Hsu, John Tsu-An, Ouchi, Toru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2013
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654437/ https://www.ncbi.nlm.nih.gov/pubmed/23678290 http://dx.doi.org/10.7150/ijbs.5806

Ejemplares similares

A Novel Aurora-A Inhibitor, BPR1K0609S1, Sensitizes Colorectal Tumor cells to 5-Fluorofracil (5-FU) Treatment
por: Shionome, Yoshimi, et al.
Publicado: (2013)

BPR1K653, a Novel Aurora Kinase Inhibitor, Exhibits Potent Anti-Proliferative Activity in MDR1 (P-gp170)-Mediated Multidrug-Resistant Cancer Cells
por: Cheung, Chun Hei Antonio, et al.
Publicado: (2011)

Integrity of p53 Associated Pathways Determines Induction of Apoptosis of Tumor Cells Resistant to Aurora-A Kinase Inhibitors
por: Shionome, Yoshimi, et al.
Publicado: (2013)

Pyrazole compound BPR1P0034 with potent and selective anti-influenza virus activity
por: Shih, Shin-Ru, et al.
Publicado: (2010)

Tubulin-Destabilizing Agent BPR0L075 Induces Vascular-Disruption in Human Breast Cancer Mammary Fat Pad Xenografts
por: Liu, Li, et al.
Publicado: (2012)

An Antimitotic and Antivascular Agent BPR0L075 Overcomes Multidrug Resistance and Induces Mitotic Catastrophe in Paclitaxel-Resistant Ovarian Cancer Cells
por: Wang, Xiaolei, et al.
Publicado: (2013)

Securin Enhances the Anti-Cancer Effects of 6-Methoxy-3-(3′,4′,5′-Trimethoxy-Benzoyl)-1H-Indole (BPR0L075) in Human Colorectal Cancer Cells
por: Tseng, Ho-Hsing, et al.
Publicado: (2012)

Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation
por: Hsu, Yung Chang, et al.
Publicado: (2016)

BPR1J373, a novel multitargeted kinase inhibitor, effectively suppresses the growth of gastrointestinal stromal tumor
por: Tsai, Hui‐Jen, et al.
Publicado: (2018)

Physiological and Oncogenic Aurora-A Pathway
por: SAEKI, Toshiaki, et al.
Publicado: (2009)

Evaluation of the Antitumor Effects of BPR1J-340, a Potent and Selective FLT3 Inhibitor, Alone or in Combination with an HDAC Inhibitor, Vorinostat, in AML Cancer
por: Lin, Wen-Hsing, et al.
Publicado: (2014)

5-FU Metabolism in Cancer and Orally-Administrable 5-FU Drugs
por: Miura, Koh, et al.
Publicado: (2010)

BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML
por: Lin, W-H, et al.
Publicado: (2012)

Mechanism of acquired 5FU resistance and strategy for overcoming 5FU resistance focusing on 5FU metabolism in colon cancer cell lines
por: Suetsugu, Tomonari, et al.
Publicado: (2021)

EU Regulation of Nanobiocides: Challenges in Implementing the Biocidal Product Regulation (BPR)
por: Brinch, Anna, et al.
Publicado: (2016)

The role of GLI1 for 5-Fu resistance in colorectal cancer
por: Zhang, Lining, et al.
Publicado: (2017)

Aspirin suppresses chemoresistance and enhances antitumor activity of 5-Fu in 5-Fu-resistant colorectal cancer by abolishing 5-Fu-induced NF-κB activation
por: Fu, Jinbo, et al.
Publicado: (2019)

No effect of dose, hepatic function, or nutritional status on 5-FU clearance following continuous (5-day), 5-FU infusion.
por: Fleming, R. A., et al.
Publicado: (1992)

Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery
por: De Angelis, Paula M, et al.
Publicado: (2006)

5-FU toxicity and nutritional deficiencies.
por: Stenram, U.
Publicado: (1993)

Fluorouracil (5-FU)-induced Cardiomyopathy
por: Thalambedu, Nishanth, et al.
Publicado: (2019)

Essential Roles of mTOR/Akt Pathway in Aurora-A Cell Transformation
por: Taga, Makoto, et al.
Publicado: (2009)

Inhibition of CDK1 Reverses the Resistance of 5-Fu in Colorectal Cancer
por: Zhu, Yiping, et al.
Publicado: (2020)

Association of 5-FU Therapeutic Drug Monitoring to DPD Phenotype Assessment May Reduce 5-FU Under-Exposure
por: Dolat, Marine, et al.
Publicado: (2020)

Eukaryotic translation initiation factor 3 subunit G (EIF3G) resensitized HCT116/5-Fu to 5-fluorouracil (5-Fu) via inhibition of MRP and MDR1
por: Yang, Chenggang, et al.
Publicado: (2018)

EPEN-30. 5FU with Radiation Followed by Maintenance of 5FU and ATRA Significantly Improves Survival of 1q+/6q- PFA Ependymoma Xenograft Models
por: Grimaldo, Enrique, et al.
Publicado: (2022)

Colloidal Assemblies Composed of Polymeric Micellar/Emulsified Systems Integrate Cancer Therapy Combining a Tumor-Associated Antigen Vaccine and Chemotherapeutic Regimens
por: Huang, Chiung-Yi, et al.
Publicado: (2021)

Observation of the Effect of Nursing BPR on Thrombolytic Efficacy and Prognosis of Patients with Cerebral Infarction Based on CT Images
por: Wang, Shaomin, et al.
Publicado: (2022)

Managing 5FU Cardiotoxicity in Colorectal Cancer Treatment
por: Anaka, Matthew, et al.
Publicado: (2022)

Whole transcriptome sequence data of 5-FU sensitive and 5-FU resistant tumors generated in a mouse model of de novo carcinogenesis
por: Iacovides, Demetris, et al.
Publicado: (2018)

Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609)
por: Liang, Xu, et al.
Publicado: (2018)

Effect of Skimmed Milk on the Absorption and Metabolism of5-Fluorouracil (5-FU) in Animals
por: Ahmad, Maqsood, et al.
Publicado: (2012)

A unique presentation of 5-fluorouracil (5-FU) induced cerebral encephalopathy
por: Naik, Shailendra S, et al.
Publicado: (2020)

Characterization of BPSS1521 (bprD), a Regulator of Burkholderia pseudomallei Virulence Gene Expression in the Mouse Model
por: Chirakul, Sunisa, et al.
Publicado: (2014)

FOXM1 modulates 5-FU resistance in colorectal cancer through regulating TYMS expression
por: Varghese, Vidhya, et al.
Publicado: (2019)

Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) ± folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients
por: Bensmaïne, M A, et al.
Publicado: (2001)

5-FU-induced cardiac toxicity - an underestimated problem in radiooncology?
por: Steger, Felix, et al.
Publicado: (2012)

5-FU induced cardiotoxicity: case series and review of the literature
por: Yuan, Cai, et al.
Publicado: (2019)

Pharmacokinetics and pharmacodynamics of locoregional 5 fluorouracil (5FU) in advanced colorectal liver metastases.
por: Goldberg, J. A., et al.
Publicado: (1988)

Novel mutual prodrug of 5-fluorouracil and heme oxygenase-1 inhibitor (5-FU/HO-1 hybrid): design and preliminary in vitro evaluation
por: Salerno, Loredana, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_epsct53q8onh2bsmaqg8p8cme9